Literature DB >> 32934048

An update on the management of cholestatic liver diseases.

Gautham Appanna1, Yiannis Kallis2.   

Abstract

Cholestatic liver diseases are a challenging spectrum of conditions arising from damage to bile ducts, leading to build-up of bile acids and inflammatory processes that cause injury to cholangiocytes and hepatocytes. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are the two most common cholestatic disorders. In this review we detail the latest guidelines for the diagnosis and management of patients with these two conditions. © Royal College of Physicians 2020. All rights reserved.

Entities:  

Keywords:  Primary biliary cholangitis; cholangiocarcinoma; primary sclerosing cholangitis; risk stratification; ursodeoxycholic acid

Mesh：

Substances：

Year:  2020        PMID： 32934048      PMCID： PMC7539742          DOI： 10.7861/clinmed.2020-0697

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


  23 in total

1.  Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.

Authors:  Ulrich Beuers; M Eric Gershwin; Robert G Gish; Pietro Invernizzi; David E J Jones; Keith Lindor; Xiong Ma; Ian R Mackay; Albert Parés; Atsushi Tanaka; John M Vierling; Raoul Poupon
Journal:  Hepatology       Date:  2015-09-15       Impact factor: 17.425

Review 2.  Ursodeoxycholic acid for the treatment of primary biliary cirrhosis.

Authors:  Keith Lindor
Journal:  N Engl J Med       Date:  2007-10-11       Impact factor: 91.245

3.  A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.

Authors:  Christophe Corpechot; Olivier Chazouillères; Alexandra Rousseau; Antonia Le Gruyer; François Habersetzer; Philippe Mathurin; Odile Goria; Pascal Potier; Anne Minello; Christine Silvain; Armand Abergel; Maryline Debette-Gratien; Dominique Larrey; Olivier Roux; Jean-Pierre Bronowicki; Jérôme Boursier; Victor de Ledinghen; Alexandra Heurgue-Berlot; Eric Nguyen-Khac; Fabien Zoulim; Isabelle Ollivier-Hourmand; Jean-Pierre Zarski; Gisèle Nkontchou; Sara Lemoinne; Lydie Humbert; Dominique Rainteau; Guillaume Lefèvre; Luc de Chaisemartin; Sylvie Chollet-Martin; Farid Gaouar; Farid-Hakeem Admane; Tabassome Simon; Raoul Poupon
Journal:  N Engl J Med       Date:  2018-06-07       Impact factor: 91.245

Review 4.  Cancer surveillance in patients with primary sclerosing cholangitis.

Authors:  Nataliya Razumilava; Gregory J Gores; Keith D Lindor
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

5.  Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group.

Authors:  R E Poupon; A M Bonnand; Y Chrétien; R Poupon
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

6.  Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study.

Authors:  J H Tabibian; E Weeding; R A Jorgensen; J L Petz; J C Keach; J A Talwalkar; K D Lindor
Journal:  Aliment Pharmacol Ther       Date:  2013-02-05       Impact factor: 8.171

Review 7.  Primary Sclerosing Cholangitis.

Authors:  Konstantinos N Lazaridis; Nicholas F LaRusso
Journal:  N Engl J Med       Date:  2016-09-22       Impact factor: 91.245

8.  Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.

Authors:  David Jones; Pol F Boudes; Mark G Swain; Christopher L Bowlus; Michael R Galambos; Bruce R Bacon; Yvonne Doerffel; Norman Gitlin; Stuart C Gordon; Joseph A Odin; David Sheridan; Markus-Alexander Wörns; Virginia Clark; Linsey Corless; Heinz Hartmann; Mark E Jonas; Andreas E Kremer; George F Mells; Peter Buggisch; Bradley L Freilich; Cynthia Levy; John M Vierling; David E Bernstein; Marek Hartleb; Ewa Janczewska; Fedja Rochling; Hemant Shah; Mitchell L Shiffman; John H Smith; Yun-Jung Choi; Alexandra Steinberg; Monika Varga; Harinder Chera; Robert Martin; Charles A McWherter; Gideon M Hirschfield
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-08-14

9.  Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

Authors:  Gideon M Hirschfield; Andrew Mason; Velimir Luketic; Keith Lindor; Stuart C Gordon; Marlyn Mayo; Kris V Kowdley; Catherine Vincent; Henry C Bodhenheimer; Albert Parés; Michael Trauner; Hanns-Ulrich Marschall; Luciano Adorini; Cathi Sciacca; Tessa Beecher-Jones; Erin Castelloe; Olaf Böhm; David Shapiro
Journal:  Gastroenterology       Date:  2014-12-11       Impact factor: 22.682

10.  Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom.

Authors:  Huifang Liang; Sudhakar Manne; Jesse Shick; Trevor Lissoos; Paul Dolin
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.817
View more
  1 in total

1.  Guidelines for the Management of Cholestatic Liver Diseases (2021).

Authors:  Lungen Lu
Journal:  J Clin Transl Hepatol       Date:  2022-04-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.